Azienda Ospedaliera Universitaria Citta' Della Salute E Della Scienza Di Torino
- Address
- Via Cherasco 15, 10126 Turin, Italy
Congenital, Hereditary, and Neonatal Diseases
The Dipartimento Pediatria e Specialita' Pediatriche at Azienda Ospedaliera Universitaria Citta' Della Salute E Della Scienza Di Torino is active in pediatric research on congenital and neonatal conditions, with studies focused on biliary atresia and infant acute lymphoblastic leukemia. These trials are aimed at improving long-term outcomes, supporting organ survival, and testing new treatment strategies for very young patients.
- Research on biliary atresia to help preserve native liver function and extend survival
- Studies in infant acute lymphoblastic leukemia to improve event-free survival in newly diagnosed disease
- Evaluation of new treatment approaches for pediatric hereditary and early-life disorders
These trials reflect a strong focus on rare and serious childhood diseases, where the goal is to refine treatment and improve outcomes for children and infants.
Hemic and Lymphatic Diseases
Clinical research in hemic and lymphatic diseases is a major area at this site, covering haemophilia, acute myeloid leukemia, acute lymphoblastic leukemia, and lymphomas. The studies are designed to evaluate new medicines, improve supportive care, and test better ways to control bleeding disorders and blood cancers in children and young adults.
- Trials in haemophilia A and related bleeding disorders to assess preventive treatment and long-term safety
- Studies in acute myeloid leukemia and acute lymphoblastic leukemia to improve response and survival
- Research in classical Hodgkin lymphoma and other lymphomas to test new immunotherapy and combination approaches
The site also contributes to research on anemia and other blood-related conditions, supporting broader efforts to improve pediatric hematology care.
Immune System Diseases
Work in immune system diseases includes studies for children with immunocompromised conditions, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome. Research here is centered on testing new therapies that may better control disease activity, prevent complications, and improve safety in vulnerable pediatric patients.
- Evaluation of treatments for PNH and aHUS to improve disease control and patient outcomes
- Studies of herpes zoster prevention in immunocompromised children and adolescents
- Investigation of immune-targeted therapies for lymphoma and other serious pediatric conditions
These trials show a broad interest in strengthening immune-related care, especially where children face high risk from infection or immune-driven disease.
Neoplasms
Oncology research is highly visible at the Turin site, with studies spanning solid tumors, leukemias, and lymphomas. The main purpose of these trials is to test new anticancer therapies, measure treatment effectiveness, and improve outcomes for children and young adults with difficult-to-treat cancers.
- Studies of pediatric solid tumors and advanced cancers to assess antitumor activity
- Trials in relapsed or refractory leukemia to explore better treatment responses
- Research in classical Hodgkin lymphoma and non-Hodgkin lymphoma to evaluate immunotherapy and combination treatment options
This area includes both newly diagnosed and relapsed disease, highlighting a strong focus on improving care where standard treatment is often not enough.
Nutritional and Metabolic Diseases
The site also conducts pediatric studies in nutritional and metabolic diseases, including type 2 diabetes mellitus and anemia associated with chronic kidney disease. These trials are intended to assess whether new treatments can improve metabolic control, support blood health, and offer better long-term management for children and adolescents.
- Research on type 2 diabetes to evaluate better glucose control and treatment safety
- Studies of anemia in chronic kidney disease to test new options for pediatric patients
- Clinical investigation aimed at improving care for metabolic and kidney-related complications
Overall, this portfolio adds important breadth to the site’s pediatric research, linking metabolic care with broader efforts in chronic disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 29 therapeutic areas and 15 of 614 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 586 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 142 by active trials.
- 1Janssen Cilag International8active
lock +141 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International22trials
lock +83 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera Universitaria Citta' Della Salute E Della Scienza Di Torino
lock Showing 1 of 523 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN". | Fondazione Radioterapia Oncologica Onlus | Phase II | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 614 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 35 | Unknown | 2015-05-05 | 2025-12-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.